BAX and cancer: The CAR‐T treatment markedly increased STAT1, cleaved‐caspase 3 and Bax expressions as the effector‐to‐target ratio increased in cancer cells, and the expression of caspase 3 was decreased to undetectable levels after exposure with CAR‐T cells (Figure 6J).